Natus Medical Incorporated Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 2/27/2022)
| Balance Sheet | Total Assets | 564,288,000.00 | ROE | – |
| Balance Sheet | Total Equity | 424,750,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -3,620,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 60,375,000.00 | – | – |
| Cashflow | Operating Cash Flow | 63,995,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 0.39 | Div. Yield | – |
| Income | Net Income | 13,177,000.00 | P/E | – |
| Income | Shares Outstanding | 33,974,000.00 | P/B | – |
| Income | Total Revenue | 473,438,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Natus Medical Incorporated (Natus) is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The Company´s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn´s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. Natus categorizes its products into three categories: Hearing, Neurology and Newborn Care. In July 2012, the Company acquired the Nicolet neurodiagnostic business from CareFusion.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.natus.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more